[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350925-105":59,"doc-detail-350925-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cell-penetrating-peptide-mediated-sirna-targeting-of-ldhc-suppresses-tumor-growth-in-a-triple-negative-breast-cancer-zebrafish-xenograft-model","Cell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model","","Lactate Dehydrogenase C (LDHC) is a tumor-specific therapeutic target with immunogenic and oncogenic roles, yet selective LDHC inhibitors are lacking. This study evaluates physicochemical properties and delivery performance of four cell-penetrating peptide (CPP) complexes—R10, 10R-RGD, cRGD-10R, and iRGD-10R—for siRNA-mediated LDHC silencing in triple-negative breast cancer (TNBC). Uniform nanocomplexes showed serum stability and low cytotoxicity, with 10R-RGD and cRGD-10R inducing ~40% LDHC knockdown, reducing clonogenicity, and enhancing olaparib sensitivity, while zebrafish xenografts exhibited ~50% tumor growth suppression with limited toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cell-penetrating-peptide-mediated-sirna-targeting-of-ldhc-suppresses-tumor-growth-in-a-triple-negative-breast-cancer-zebrafish-xenograft-model/350925/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cell-penetrating-peptide-mediated-sirna-targeting-of-ldhc-suppresses-tumor-growth-in-a-triple-negative-breast-cancer-zebrafish-xenograft-model/350925.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is LDHC considered a promising target in triple-negative breast cancer?","Question",{"text":112,"@type":113},"LDHC shows highly tumor-specific expression and contributes oncogenic functions, with links to tumor progression, metastasis, and poor prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the CPP-siRNA formulations evaluated in this study?",{"text":117,"@type":113},"The work assessed physicochemical properties, delivery efficiency, anti-tumor activity, and safety across in vitro assays and TNBC zebrafish xenografts, including clonogenic assays for drug sensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"Which peptide formulations performed best and what were the key outcomes?",{"text":121,"@type":113},"10R-RGD and cRGD-10R produced ~40% LDHC protein knockdown, reduced TNBC clonogenicity, enhanced sensitivity to olaparib, and reduced tumor growth in zebrafish xenografts by about 50% with major toxicity not emphasized.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350925,1790431393,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nCell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model  \nHanan Qasem 1,2, Adviti Naik 2,†, Tricia Gomez 3, Janarthanan Ponraj 3, Umar Jafar 1,2, Martin Sikhondze 2, Remy Thomas 2, Khaled A. Mahmoud 3 and Julie Decock 1,2, *  \nAcademic Editor: Francisco Javier Otero-Espinar  \nReceived: 5 December 2025  \nRevised: 26 December 2025  \nAccepted: 3 January 2026  \nPublished: 7 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar; [hqasem@hbku.edu.qa](hqasem@hbku.edu.qa) (H.Q.); [umja44783@hbku.edu.qa](umja44783@hbku.edu.qa) (U.J.)  \n2 Translational Oncology Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar; [advitin@andrew.cmu.edu](advitin@andrew.cmu.edu) (A.N.); [msikhond@alumni.cmu.edu](msikhond@alumni.cmu.edu) (M.S.)  \n3 Qatar Environment and Energy Research Institute (QEERI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar; [tgomez@hbku.edu.qa](tgomez@hbku.edu.qa) (T.G.); [jponraj@hbku.edu.qa](jponraj@hbku.edu.qa) (J.P.); [kmahmoud@hbku.edu.qa](kmahmoud@hbku.edu.qa) (K.A.M.)  \n* [Correspondence: jdecock@hbku.edu.qa](Correspondence: jdecock@hbku.edu.qa)  \n† Current address: Biological Sciences, Carnegie Mellon University in Qatar, Doha P.O. Box 24866, Qatar.  \nAbstract  \nBackground: Lactate Dehydrogenase C (LDHC) is a promising therapeutic target due to its highly tumor-specific expression, immunogenicity, and oncogenic functions. We previously showed that LDHC silencing in triple-negative breast cancer (TNBC) cells enhances treatment response to DNA-damage response-related drugs, supporting its therapeutic potential. However, no selective LDHC inhibitors exist, highlighting the need for innovative targeting strategies. Methods: We assessed the physicochemical properties and evaluated the delivery efficiency, anti-tumor activity, and safety of four cell-penetrating peptides (CPPs)—R10, 10R-RGD, cRGD-10R, and iRGD-10R—for siRNA-mediated LDHC silencing in TNBC. Clonogenic assays were used to evaluate effects on olaparib sensitivity, and TNBC zebrafish xenografts were utilized to study in vivo anti-tumor activity. Results: All CPP:siRNA complexes formed uniform nanocomplexes (129–168 nm) with low polydispersity indices (\u003C0.25) and positive zeta potentials (+6.47 to +29.6 mV) . Complexes remained stable in human serum for 24 h and showed no significant cytotoxicityin TNBC and non-cancerous cell lines. The 10R-RGD and cRGD-10R:siLDHC complexes achieved 40% LDHC protein knockdown, reduced TNBC clonogenicity by 30–36%, and enhanced olaparib sensitivity. Treatment of TNBC zebrafish xenografts with 10R-RGD or cRGD-10R:siLDHC complexes significantly reduced tumor growth by approximately 50% without major toxicity. Conclusions: These results demonstrate that CPP-mediated siRNA delivery enables selective LDHC silencing with tumor growth inhibition in triple-negative breast cancer models. This approach represents a novel, effective, and safe proof-of-concept therapeutic strategy to target LDHC, with potential translational relevance as a standalone therapy or in combination with common anti-cancer drugs.  \nKeywords: LDHC; Lactate Dehydrogenase C; CPP; cell penetrating peptide; siRNA therapeutics; triple negative breast cancer  \n1. Introduction  \nBreast cancer is the most prevalent cancer and the leading cause of mortality among women worldwide [1] . Triple-negative breast cancer (TNBC), characterized by the lack of expression of the estrogen receptor, progesterone receptor, and Human Epidermal Growth Factor Receptor 2 ","cbCairkdVJHJZwd1","https://ap.wps.com/l/cbCairkdVJHJZwd1","pdf",4950945,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# 1. Introduction\n## Triple-negative breast cancer overview\n## Precision medicine and combination therapies\n## LDHC as a therapeutic target","[{\"question\":\"Why is LDHC considered a promising target in triple-negative breast cancer?\",\"answer\":\"LDHC shows highly tumor-specific expression and contributes oncogenic functions, with links to tumor progression, metastasis, and poor prognosis.\"},{\"question\":\"How were the CPP-siRNA formulations evaluated in this study?\",\"answer\":\"The work assessed physicochemical properties, delivery efficiency, anti-tumor activity, and safety across in vitro assays and TNBC zebrafish xenografts, including clonogenic assays for drug sensitivity.\"},{\"question\":\"Which peptide formulations performed best and what were the key outcomes?\",\"answer\":\"10R-RGD and cRGD-10R produced ~40% LDHC protein knockdown, reduced TNBC clonogenicity, enhanced sensitivity to olaparib, and reduced tumor growth in zebrafish xenografts by about 50% with major toxicity not emphasized.\"}]","Cell-Penetrating Peptide-Mediated siRNA Targeting of LDHC Suppresses Tumor Growth in a Triple-Negative Breast Cancer Zebrafish Xenograft Model | PDF",1790091797,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8093a2cd7c3f7da3e23ae66d212019d.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21a6b111f6a6952861d27a75d3ca89d9.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12b440954c068f47af5a0387f696abda.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a841f11f5ec0e440db0370c6a3df0fa.webp",980,1385]